Neumora Therapeutics (NMRA) Company presentation summary

Mission and leadership

• Focused on developing next-generation, brain-penetrant therapies to improve outcomes and quality of life for patients with neurological and psychiatric disorders.

• Led by experienced executives and board members with backgrounds in major pharmaceutical and biotech companies.

Strategic focus and market opportunity

• Targeting large unmet needs in neuropsychiatric, neurodegenerative, and cardiometabolic diseases, which impact millions in the U.S.

• Programs aim to provide novel mechanisms, improved tolerability, and oral treatment options for these conditions.

Pipeline and clinical development

• Advancing three main franchises: NMRA-215 (obesity/cardiometabolic), NMRA-511 (Alzheimer’s agitation), and NMRA-898 (schizophrenia).

• NMRA-215: Differentiated NLRP3 inhibitor showing class-leading weight loss, improved metabolic biomarkers, and potential for combination therapy with semaglutide.

• NMRA-511: V1aR antagonist with strong efficacy and safety in Alzheimer’s agitation, especially in patients with elevated anxiety.

• NMRA-898: M4 muscarinic receptor PAM for schizophrenia, optimized for CNS exposure and potency, with promising Phase 1 results.